【Claims】

1. A single strand oligonucleotide comprising a nucleotide sequence motif 5'-tcgcaacgttt-n-cgacg-n-cg-nn-cg -3' (SEQ ID NO:2), wherein n denotes any base.

2. The oligonucleotide according to claim 1, wherein the total base number is 24 or 25.

3. The oligonucleotide according to claim 1 or 2, wherein the oligonucleotide comprises a sequence motif selected from the group consisting of the followings:

5'-tcgcaacgtttgcgacgtcggtcga (SEQ ID NO:54);
5'-tcgcaacgtttgcgacggcgctcga (SEQ ID NO:55);
5'-tcgcaacgtttgcgacgtcgttcga (SEQ ID NO:56);
5'-tcgcaacgtttgcgacggcgttcga (SEQ ID NO:57);
5'-tcgcaacgtttgcgacgtcgttcg (SEQ ID NO:58);
5'-tcgcaacgtttgcgacgtcgttcgg (SEQ ID NO:59);
5'-tcgcaacgtttacgacgtcggtcga (SEQ ID NO:60);
5'-tcgcaacgtttacgacggcgctcga (SEQ ID NO:61);
5'-tcgcaacgtttacgacgtcgttcga (SEQ ID NO:62); and
5'-tcgcaacgtttacgacggcgttcga (SEQ ID NO:63).

4. The oligonucleotide according to any one of claims 1-3, wherein the internucleotide linkage(s) of the oligonucleotide is partially or fully chemically modified.

5. The oligonucleotide according to claim 4, wherein the chemically-modified internucleotide linkage is phosphorothioated.

6. The oligonucleotide according to claim 5, wherein the oligonucleotide comprises a partially phosphorothioated oligonucleotide stretch selected from the group consisting of

5'-tCgcaacgtttgcgacgtcgttcgA-3' (SEQ ID NO:16);
5'-tCgcaaCgtttgcgacgtcgttcgA-3' (SEQ ID NO:17);
5'-tCgCaaCgtttgcgacgtcgttcgA-3' (SEQ ID NO:18);
5'-tCgCaacgtttgCgaCgtcgttcgA-3' (SEQ ID NO:19);
5'-tCgCaacgtttgCgaCgtcgttCgA-3' (SEQ ID NO:20);
5'-tCgCaaCgtttgcgacgtCgttCgA-3' (SEQ ID NO:21);
5'-tCgCaaCgtttgCgaCgtCgttCgA-3' (SEQ ID NO:22);
5'-tCgCaaCgtttgcgacgtCggtCgA-3' (SEQ ID NO:23);
5'-tCgCaaCgtttgcgacggCgctCgA-3' (SEQ ID NO:24);
5'-tCgCaaCgtttgcgacggCgttCgA-3' (SEQ ID NO:26);
5'-tCgCaaCgtttgcgacgcCgttCgA-3' (SEQ ID NO:27);
5'-tCgCaaCgtttgcgacggCgtaCgA-3' (SEQ ID NO:28);
5'-tCgCaaCgtttgcgacggCgtgCgA-3' (SEQ ID NO:29);
5'-tCgCaaCgtttacgacgtCggtCgA-3' (SEQ ID NO:30);
5'-tCgCaaCgtttacgacggCgctCgA-3' (SEQ ID NO:31);
5'-tCgCaaCgtttacgacgtCgttCgA-3' (SEQ ID NO:32);
5'-tCgCaaCgtttGcgacgtCggtCgA-3' (SEQ ID NO:33);
5'-tCgCaaCgtttAcgacgtCggtCgA-3' (SEQ ID NO:34);
5'-tCgCaaCgtttGcgacggCgctCgA-3' (SEQ ID NO:35);
5'-tCgCaaCgtttAcgacggCgctCgA-3' (SEQ ID NO:36);
5'-tCgCaaCgtttGcgacgtCgttCgA-3' (SEQ ID NO:37);
5'-tCgCaaCgtttAcgacgtCgttCgA-3' (SEQ ID NO:38);
5'-tCgCaaCgtttGcgacgtCggtCgG-3' (SEQ ID NO:39);
5'-tCgCaaCgtttAcgacgtCggtCgG-3' (SEQ ID NO:40);

5’-tCgCaaCgtttGcgacggCgctCgG-3’ (SEQ ID NO:41);
5’-tCgCaaCgtttAcgacggCgctCgG-3’ (SEQ ID NO:42);
5’-tCgCaaCgtttGcgacgtCgttCgG-3’ (SEQ ID NO:43); and
5’-tCgCaaCgtttAcgacgtCgttCgG-3’ (SEQ ID NO:44);
wherein the capital letter denotes a nucleoside with no modified internucleotide linkage at 3’, and the small letter denotes a nucleoside with an internucleotide linkage with phosphorothioation at 3’.

7. The oligonucleotide according to claim 5, wherein the oligonucleotide comprises a partially phosphorothioated oligonucleotide stretch selected from the group consisting of,
5’-tCgCaaCgtttgcgacggCgctCgA-3’ (SEQ ID NO:24);
5’-tCgCaaCgtttGcgacgtCggtCgA-3’ (SEQ ID NO:33);
5’-tCgCaaCgtttAcgacgtCggtCgA-3’ (SEQ ID NO:34);
5’-tCgCaaCgtttGcgacggCgctCgA-3’ (SEQ ID NO:35); and
5’-tCgCaaCgtttAcgacggCgctCgA-3’ (SEQ ID NO:36),
wherein the capital letter denotes a nucleoside with no modified internucleotide linkage at 3’, and the small letter denotes a nucleoside with an internucleotide linkage with phosphorothioation at 3’.

8. The oligonucleotide according to any one of claims 1-7, wherein the oligonucleotide is constituted with DNA.

9. The oligonucleotide according to any one of claims 1-8, which is conjugated with at least one active molecule.

10. The oligonucleotide according to claim 9, wherein the active molecule is selected from the group consisting of (poly)peptides/antibodies and nucleic acids/oligonucleotides.

11. A pharmaceutical composition, comprising a therapeutically effective amount of the oligonucleotide according to any one of claims 1 - 10 or a therapeutically effective amount of a double-strand oligonucleotide comprising the oligonucleotide according to any one of claims 1 - 11; and a pharmaceutical acceptable carrier.

12. The pharmaceutical composition according to claim 11, for use in the prophylaxis or treatment of a target disease or disorder, wherein the target disease or disorder is any one selected from the group consisting of neoplasms, infectious disease, disease related to Th2/Th17, primary immunodeficiency disease caused by a lack of functional TLR-related systems, and Post-traumatic stress disorder (PTSD).

13. The pharmaceutical composition according to claim 11 or 13, wherein the composition further comprises at least one active ingredient.

14. The pharmaceutical composition according to any one of claim 13 or 14, wherein the composition is to be co-administered with at least one active ingredient.

15. The pharmaceutical composition according to claim 13 or 14, wherein the active ingredient is selected from the group consisting of anti-cancer drugs; molecular targeting drugs including tyrosine kinase inhibitors, angiogenesis inhibitors and proteasome inhibitors; anti-cancer antibody drugs; cytokines; vaccines; antibacterial agents; antifungul agents; antivirus agents; antiparasitic drugs; antibody drugs to neutralize toxin; agonists of other TLRs and combination thereof.

16. The pharmaceutical composition according to claim 12, wherein the target disease or disorder is
1) a neoplasm selected from the group consisting of malignant neoplasm, epithelial neoplasm or hematopoietic organ tumor, sarcoma, mesothelioma, benign tumor, dysplasia and metaplasia;.
2) an infectious disease caused by microorganisms including viruses, bacteria, and fungi;
3) a disease related to Th2/Th17 selected from the group consisting of asthma, allergies, multiple sclerosis, Inflammatory Bowel Disease including ulcerative colitis and Crohn disease, cutaneous lichen planus and Alzheimer's disease;or
4) a primary immunodeficiency disease caused by IRAK4 deficiency, MyD88 deficiency, Unc93B deficiency or mutations in TLRs.

17. The pharmaceutical composition according to claim 11 or 12, wherein the composition is to be administered before or after adoptive immune cell therapies or surgical treatments including radiation therapy, cryoablation, radiofrequency ablation and photodynamic therapy (PDT).

18. Use of the single strand oligonucleotide according to any one of claims 1-10 or a double-strand oligonucleotide comprising the single strand oligonucleotide according to any one of claims 1-10, in the manufacture of a medicament for treatment or prophylaxis of a target disease or disorder selected from the group consisting of neoplasms, infectious disease, disease related to Th2/Th17, primary immunodeficiency disease caused by a lack of functional TLR-related systems, and Post traumatic stress disorder (PTSD).

19. The use according to 18, wherein the target disease or disorder is
1) a neoplasm selected from the group consisting of malignant neoplasm, epithelial neoplasm or hematopoietic organ tumor, sarcoma, mesothelioma, benign tumor, dysplasia and metaplasia;
2) an infectious disease caused by microorganisms including viruses, bacteria, or fungi;
3) a disease related to Th2/Th17 selected from the group consisting of asthma, atopic disease, Inflammatory Bowel Disease including ulcerative colitis and Crohn disease, cutaneous lichen planus and Alzheimer's disease; or
4) a primary immunodeficiency disease caused by IRAK4 deficiency, MyD88 deficiency, Unc93B deficiency or mutations in TLRs.